Pembrolizumab indication expanded

The anti-PD-1 drug pembrolizumab (Keytruda, MSD) has been approved by the TGA for the treatment of refractory or relapsed Hodgkin’s lymphoma.

The approval is for monotherapy with 200mg every three weeks in adults with classical Hodgkin lymphoma following autologous stem cell transplant or at least two prior therapies when autologous transplant or multi-agent chemotherapy is not an option.

The TGA approval follows the KEYNOTE-087 trial in 210 patients with relapsed or refractory disease, that showed an overall